PharmaCyte Biotech
PMCB
PMCB
29 hedge funds and large institutions have $2.32M invested in PharmaCyte Biotech in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Holders
29
Holding in Top 10
–
Calls
$63K
Puts
$1K
Top Buyers
| 1 | +$54.2K | |
| 2 | +$45.4K | |
| 3 | +$13.5K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.74K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.21K |
Top Sellers
| 1 | -$178K | |
| 2 | -$47.5K | |
| 3 | -$36.4K | |
| 4 |
Bank of New York Mellon
New York
|
-$35.9K |
| 5 |
Squarepoint
New York
|
-$32.1K |